Skip to main content

Table 5 Inter- and intra-reader performance results

From: Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Study outline Design Inter-reader, %
(95 % CI)
Intra-reader, %
(95 % CI)
NSCLC cases: inter- and intra-reader agreement on a cohort previously screened for PD-L1 status 81 cases
40 PD-L1 high
41 PD-L1 low/negative
APA 96.6 % (93.8–98.8)
ANA 96.8 % (93.9–98.9)
OPA 96.7 % (94.2–98.9)
APA 96.2 % (92.7–98.8)
ANA 96.4 % (93.0–98.8)
OPA 96.3 % (93.3–98.8)
HNSCC cases: inter- and intra- reader agreement on a cohort previously screened for PD-L1 status 100 cases
50 PD-L1 high
50 PD-L1 low/negative
APA 90.9 % (86.0–94.9)
ANA 90.8 % (86.0–94.8)
OPA 90.8 % (86.7–94.7)
APA 94.4 % (91.1–97.1)
ANA 94.3 % (91.0–97.1)
OPA 94.3 % (91.3–97.0)
  1. ANA average negative agreement, APA average positive agreement, CI confidence interval, HNSCC head and neck squamous cell carcinoma, NSCLC non-small cell lung cancer, OPA overall percentage agreement, PD-L1 programmed cell death ligand-1